Clinical Trials

Phase 1 Active not recruiting

362 enrolled

Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05891171 2026-02-27

ARC-25

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Phase 1 Active not recruiting

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

182 enrolled

Solid Tumor

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

416 enrolled

Phase 1 Active not recruiting

Advanced Solid Tumor

NCT06082960 2025-09-10

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

45 enrolled

Solid Tumors

NCT04772989 2025-08-28

ARC-12

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

94 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT06532565 2025-05-16

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

154 enrolled

Advanced Solid Tumors

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

75 enrolled

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

77 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

18 enrolled

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled 18 charts